This document discusses the categorization of herbal products in Europe as either traditional herbal medicinal products or traditional plant food supplements. While regulations have established these as distinct categories, in practice there is significant overlap between the two. Many botanical species are marketed as both food supplements in some countries and medicinal products in others. Examples are provided of botanicals registered as medicinal products in some countries that are commonly used as supplements in many others. The categorization of herbal products in Europe depends more on tradition and national practices than intrinsic properties.
This document discusses the categorization of herbal products in Europe and the different regulatory approaches taken by the European Medicines Agency (EMA) and European Food Safety Authority (EFSA). The EMA recognizes herbal medicines with traditional use claims or those with well-established use based on pharmacological data. However, the EFSA applies similar stringent evidence standards to herbal supplements as medicines, which has resulted in few traditional claims being accepted. The document argues for a more consistent regulatory approach between herbal medicines and supplements, and proposes some plants be transferred between categories or dosed based on physiological impact rather than medical claims.
The document discusses efforts to harmonize regulations on botanicals between Belgium, France, and Italy. It outlines Belgium's regulatory system for botanicals and the BELFRIT project, which aims to harmonize the evaluation of botanicals in food supplements. The first phase of BELFRIT involved combining lists of authorized plants from the three countries and researching the plants' traditional uses and safety information. This resulted in a harmonized list of over 1,000 plants. Future phases will focus on further integrating the lists into national legislation and improving scientific advice exchange. The project aims to establish a coherent regulatory system across countries based on scientific evidence and traditional knowledge.
The document summarizes the history and study of pharmacognosy and plant chemistry. It discusses how pharmacognosy originated from the study of medicinal plants and animals used in early civilizations. It then outlines the major developments in pharmacognosy over time, including early writings from ancient Mesopotamia and Egypt, the contributions from various medical traditions like Ayurveda and Unani, and the advances during the Greek, European, and modern eras. The document also reviews literature related to Philippine traditional medicine, including ethnographic studies of practices, inventories of medicinal plants, and pharmacological research.
“EFSA lacks autonomy, it is subject to the lobbies.
Its mode of operation must be revised from top to bottom.”
JOSÉ BOVÉ
http://elproyectomatriz.wordpress.com/2011/06/14/efsa-agencia-europea-de-seguridad-alimentaria-%c2%bfseguridad/
The document discusses various natural and synthetic sources of drugs, including plants, animals, microbes, minerals, and biotechnology. It notes that plants have historically been the most common source of drugs, with parts like leaves, stems, bark, fruits, and roots utilized. The document also outlines specific examples of drugs derived from each source, such as morphine from plants, beeswax from animals, penicillin from microbes, and recombinant human insulin from biotechnology.
Pharmacognosy is the study of crude drugs from natural sources including plants, animals, and minerals. It involves a systematic study of the crude drug including its description, biological source, geographical source, morphology, microscopic characteristics, chemical constituents, pharmacological actions, and other details. The subject has played a role in the development of other disciplines like botany, plant chemistry, and pharmaceutical sciences. Crude drugs can be organized, consisting of plant or animal tissues and cells, or unorganized, obtained from extraction processes and described based on physical properties. Unorganized crude drugs include dried juices, dried lattices, dried extracts, and oleo-gum resins. Pharmacognosy provides a link between various medical systems by
This document provides an introduction to Volume 4 of the WHO monographs on selected medicinal plants. It describes the increasing role and impact of the WHO monographs, and outlines the process undertaken for the selection and preparation of the 28 new monographs included in this volume. Key points include expanded international expert involvement, changes made to the monograph format to incorporate additional indexes, and the goal of building national capacity for developing regional and traditional medicine monographs.
This document discusses the categorization of herbal products in Europe and the different regulatory approaches taken by the European Medicines Agency (EMA) and European Food Safety Authority (EFSA). The EMA recognizes herbal medicines with traditional use claims or those with well-established use based on pharmacological data. However, the EFSA applies similar stringent evidence standards to herbal supplements as medicines, which has resulted in few traditional claims being accepted. The document argues for a more consistent regulatory approach between herbal medicines and supplements, and proposes some plants be transferred between categories or dosed based on physiological impact rather than medical claims.
The document discusses efforts to harmonize regulations on botanicals between Belgium, France, and Italy. It outlines Belgium's regulatory system for botanicals and the BELFRIT project, which aims to harmonize the evaluation of botanicals in food supplements. The first phase of BELFRIT involved combining lists of authorized plants from the three countries and researching the plants' traditional uses and safety information. This resulted in a harmonized list of over 1,000 plants. Future phases will focus on further integrating the lists into national legislation and improving scientific advice exchange. The project aims to establish a coherent regulatory system across countries based on scientific evidence and traditional knowledge.
The document summarizes the history and study of pharmacognosy and plant chemistry. It discusses how pharmacognosy originated from the study of medicinal plants and animals used in early civilizations. It then outlines the major developments in pharmacognosy over time, including early writings from ancient Mesopotamia and Egypt, the contributions from various medical traditions like Ayurveda and Unani, and the advances during the Greek, European, and modern eras. The document also reviews literature related to Philippine traditional medicine, including ethnographic studies of practices, inventories of medicinal plants, and pharmacological research.
“EFSA lacks autonomy, it is subject to the lobbies.
Its mode of operation must be revised from top to bottom.”
JOSÉ BOVÉ
http://elproyectomatriz.wordpress.com/2011/06/14/efsa-agencia-europea-de-seguridad-alimentaria-%c2%bfseguridad/
The document discusses various natural and synthetic sources of drugs, including plants, animals, microbes, minerals, and biotechnology. It notes that plants have historically been the most common source of drugs, with parts like leaves, stems, bark, fruits, and roots utilized. The document also outlines specific examples of drugs derived from each source, such as morphine from plants, beeswax from animals, penicillin from microbes, and recombinant human insulin from biotechnology.
Pharmacognosy is the study of crude drugs from natural sources including plants, animals, and minerals. It involves a systematic study of the crude drug including its description, biological source, geographical source, morphology, microscopic characteristics, chemical constituents, pharmacological actions, and other details. The subject has played a role in the development of other disciplines like botany, plant chemistry, and pharmaceutical sciences. Crude drugs can be organized, consisting of plant or animal tissues and cells, or unorganized, obtained from extraction processes and described based on physical properties. Unorganized crude drugs include dried juices, dried lattices, dried extracts, and oleo-gum resins. Pharmacognosy provides a link between various medical systems by
This document provides an introduction to Volume 4 of the WHO monographs on selected medicinal plants. It describes the increasing role and impact of the WHO monographs, and outlines the process undertaken for the selection and preparation of the 28 new monographs included in this volume. Key points include expanded international expert involvement, changes made to the monograph format to incorporate additional indexes, and the goal of building national capacity for developing regional and traditional medicine monographs.
An allergen is a type of antigen that triggers an exaggerated immune response in sensitive individuals. Common allergens include plant pollens, molds, animal dander, dust mites, latex, and certain foods. The document lists several specific plant pollens and fungi that are common allergens, including timothy grass, ragweed, mugwort, nettle, plantain, and Cladosporium mold. Contact with urushiol, a compound found in plants like poison ivy and poison oak, can also cause a skin rash.
1) Pharmacognosy is the study of drugs from natural sources, especially medicinal plants. It draws from fields like botany, chemistry, and pharmacology.
2) Many important drugs were originally derived from plants, including morphine, quinine, taxol, and physostigmine. Extracting and isolating the active compounds from plants was an important early step in drug development.
3) While many plant-derived drugs can now be synthesized, plants remain an important source of new drug leads and templates for designing novel pharmaceuticals due to their vast chemical diversity and potential for novel structures. Extensive further screening of plants is still needed.
The importance of medicinal plants in the treatment of a variety of human ailments man has been dependent on the higher plants as a source of food and medicine.
These slides represent a comprehensive view of history of using natural products caused to appearance of pharmacognosy as a science and show several aspects of pharmacognosy and natural products use and final their importance in discovering new drugs.
2 1-natural sources and products of plants - typesTysonMuungo
This document provides an overview of pharmacognosy and natural products, focusing on anthraquinone glycosides and senna. It defines pharmacognosy and outlines the types of plants, natural occurring chemical entities, medicinal plant harvesting, and principles of botany. It then discusses anthraquinone glycosides, their structures, properties, and examples found in plants like senna, rhubarb, and cascara. The document provides details on senna, including its constituents, collection, comparison of different varieties, substitutes, and uses as a laxative.
This slide contains definition of pharmacognosy and reverse pharmacognosy, steps of pharmacognosy, parts of reverse pharmacognosy, comparison of pharmacognosy and reverse pharmacognosy, Selnergy, Selnergy in reverse pharmacognosy, application and advantages of reverse pharmacognosy, Selnergy on e-viniferin, Conclusion and Reference.
The document discusses zoopharmacognosy, which is the animal use of plant drugs for self-medication. It provides several examples of non-human primates using medicinal plants, including chimpanzees consuming Aspilia mossambicensis leaves which contain thiarubrine A with anti-parasitic properties. It also describes capuchin monkeys engaging in fur-rubbing behavior with volatile oil-containing plants, and chimpanzees consuming various plants like Ficus exasperata containing compounds like 5-methoxypsoralen that are toxic to parasites. The document outlines similarities between human and primate self-medication and highlights challenges in distinguishing nutrition from medication in animal plant use.
Pharmacognosy has a long history dating back to primitive times when humans first used plants and other natural sources as food and medicine. Knowledge of natural remedies continued to develop through the pre-Christian era and early Christian times. Modern pharmacognosy emerged as a formal scientific discipline in the 19th century when advances in chemistry allowed closer study of biologically active plant compounds.
Pharmacognosy is the study of medicinal plants and natural products. The term was introduced in 1815 and comes from Greek roots meaning "drug" and "knowledge." It involves the study of plants as potential drug sources from pre-historic use through various civilizations like Chinese, Babylonian, Egyptian, Indian, and Greek. Modern pharmacognosy has broad applications in medicine, agriculture, cosmetics, and other industries and offers career opportunities in academia, private industry, and government.
Pharmacognosy is the study of drugs from natural sources such as plants, animals, and minerals. It developed from ancient civilizations using plant and animal parts for medicine. Through trial and error, early humans acquired knowledge about healing properties and passed this down generations. Modern pharmacognosy involves scientifically studying crude drugs, classifying them, and establishing standards for identification, quality, and purity in pharmacopoeias like the Indian Pharmacopoeia to ensure safety and efficacy of natural medicines.
Pharmacognosy is the study of medicines derived from natural sources. It deals with the physical, chemical, biochemical and biological properties of drugs from natural origins, as well as the search for new drugs. The history of pharmacognosy dates back to ancient civilizations in China, India, Egypt and Greece where plants were used medicinally before the beginning of the Christian era. Modern pharmacognosy developed between 1934-1960 due to events like the discovery of penicillin and isolation of compounds like reserpine. Today, pharmacognosy plays an important role in drug development through the isolation of active constituents, elucidation of their structures, and use of natural products as precursors for drug synthesis. Its future prospects
This document provides an introduction and overview of pharmacognosy. It defines pharmacognosy as the study of medicinal products from natural sources, including plants, animals, and minerals. The document then discusses the historical development of pharmacognosy from ancient civilizations like Babylon, Egypt, India, Greece, and China to modern developments. It also outlines the scope of pharmacognosy, including isolation of phytochemicals, structure-activity relationships, cultivation of medicinal plants, herbal formulations, and investigation of biosynthetic pathways. Finally, it briefly introduces some traditional medicine systems like Ayurveda, Unani, Siddha, and Homeopathy.
Introduction of Pharmacognosy, Scope and Traditional system of MedicineSHIVANEE VYAS
The term Pharmacognosy comes from two Greek words: “Pharmakon" meaning drug or medicine, and "gnosis" meaning knowledge or study. Pharmacognosy also defined as the systemic study of crude drugs obtained from natural origin like plants, animals, minerals, and microbes. Pharmacognosy defined as the branch of science which involves details study of drug obtained from natural origin including name, collection, cultivation, macroscopy, microscopy, physical property, chemical constituents, therapeutic action and uses.
https://youtu.be/gxOVfntCCB8
Pherecydes Pharma has launched the Phagoburn clinical trial, the first international clinical study to evaluate the effectiveness of phage therapy in treating serious bacterial infections in burn victims. The randomized, controlled trial will involve 220 patients across 11 hospitals in France, Switzerland, and Belgium. If shown to be safe and effective, phage therapy could provide an alternative or supplement to antibiotics for treating antibiotic-resistant infections.
Pharmacognosy deals with plants and animals that yield drug substances, their properties, methods of harvesting crude drugs, processing, storing, and extracting active constituents. It also involves the identification, cultivation, collection, drying, and other processing of crude drugs. Key factors that affect medicinal plants include environmental conditions, soil contents, growth regulators, and genetics. Proper identification of the biological and geographical source of crude drugs is important for ensuring the right material is obtained.
There are four main sources of drugs:
1) Natural sources including plants, animals, microorganisms, and minerals. Plants have historically been an important source and provide drugs like morphine, codeine, and digitalis.
2) Semi-synthetic drugs which are produced from natural compounds through chemical processing to make them less impure, like 6-aminopencillanic acid.
3) Synthetic drugs which are produced entirely in pharmaceutical laboratories and account for over 90% of drugs today. Examples include older drugs like chloroform as well as newer antipyretics, sulphonamides, and anti-anxiety drugs.
4) Recombinant DNA technology allows production of drugs like
Why Genetically Modified Maize Should Be BannedSeeds
The document summarizes concerns about the genetically modified maize 1507, which is tolerant to the herbicide glufosinate and produces an insecticide. It argues that the maize poses risks to the environment and biodiversity if cultivated commercially due to gaps in its risk assessment. Specifically, the effects of the maize's herbicide tolerance and impacts on non-target organisms like butterflies, bees and soil life have not been adequately studied. The European Food Safety Authority is criticized for not requiring further studies before approval and for proposing insufficient monitoring plans. Approval of the maize for cultivation is not recommended.
Pharmacognosy is "the study of the physical, chemical, biochemical and biological properties of drugs, drug substances or potential drugs or drug substances of natural origin as well as the search for new drugs from natural sources".
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
Herbal Ingredient in Food Suppliments By Anton.pptRehanAnis1
1. The document discusses establishing clear rules for evaluating the safety and efficacy of herbal ingredients in food supplements. It proposes a decision tree to differentiate products based on intended use and potential risks.
2. A procedure is outlined for evaluating safety based on the plant, extraction method, exposure, and available data. Dossiers would document quality control. Physiological effects are separated from pathological claims.
3. Indications considered physiological include heart health, capillary fragility, and minor issues. Therapeutic claims are proposed for vein issues, diarrhea, pain, and mild infections. Clear labelling is important to avoid misunderstanding about effectiveness.
This document discusses herbal cough remedies and regulation of herbal medicines. It provides epidemiological data showing widespread use of herbal medicines globally, with up to 80% of the population in Africa using traditional herbal medicine. Herbal medicines account for a significant portion of the pharmaceutical market. The document then reviews WHO guidelines for quality, safety and efficacy assessment of herbal medicines and compares regulation standards between countries like Germany, Egypt, and the United States. It also lists some common herbal cough remedies available in Egypt.
An allergen is a type of antigen that triggers an exaggerated immune response in sensitive individuals. Common allergens include plant pollens, molds, animal dander, dust mites, latex, and certain foods. The document lists several specific plant pollens and fungi that are common allergens, including timothy grass, ragweed, mugwort, nettle, plantain, and Cladosporium mold. Contact with urushiol, a compound found in plants like poison ivy and poison oak, can also cause a skin rash.
1) Pharmacognosy is the study of drugs from natural sources, especially medicinal plants. It draws from fields like botany, chemistry, and pharmacology.
2) Many important drugs were originally derived from plants, including morphine, quinine, taxol, and physostigmine. Extracting and isolating the active compounds from plants was an important early step in drug development.
3) While many plant-derived drugs can now be synthesized, plants remain an important source of new drug leads and templates for designing novel pharmaceuticals due to their vast chemical diversity and potential for novel structures. Extensive further screening of plants is still needed.
The importance of medicinal plants in the treatment of a variety of human ailments man has been dependent on the higher plants as a source of food and medicine.
These slides represent a comprehensive view of history of using natural products caused to appearance of pharmacognosy as a science and show several aspects of pharmacognosy and natural products use and final their importance in discovering new drugs.
2 1-natural sources and products of plants - typesTysonMuungo
This document provides an overview of pharmacognosy and natural products, focusing on anthraquinone glycosides and senna. It defines pharmacognosy and outlines the types of plants, natural occurring chemical entities, medicinal plant harvesting, and principles of botany. It then discusses anthraquinone glycosides, their structures, properties, and examples found in plants like senna, rhubarb, and cascara. The document provides details on senna, including its constituents, collection, comparison of different varieties, substitutes, and uses as a laxative.
This slide contains definition of pharmacognosy and reverse pharmacognosy, steps of pharmacognosy, parts of reverse pharmacognosy, comparison of pharmacognosy and reverse pharmacognosy, Selnergy, Selnergy in reverse pharmacognosy, application and advantages of reverse pharmacognosy, Selnergy on e-viniferin, Conclusion and Reference.
The document discusses zoopharmacognosy, which is the animal use of plant drugs for self-medication. It provides several examples of non-human primates using medicinal plants, including chimpanzees consuming Aspilia mossambicensis leaves which contain thiarubrine A with anti-parasitic properties. It also describes capuchin monkeys engaging in fur-rubbing behavior with volatile oil-containing plants, and chimpanzees consuming various plants like Ficus exasperata containing compounds like 5-methoxypsoralen that are toxic to parasites. The document outlines similarities between human and primate self-medication and highlights challenges in distinguishing nutrition from medication in animal plant use.
Pharmacognosy has a long history dating back to primitive times when humans first used plants and other natural sources as food and medicine. Knowledge of natural remedies continued to develop through the pre-Christian era and early Christian times. Modern pharmacognosy emerged as a formal scientific discipline in the 19th century when advances in chemistry allowed closer study of biologically active plant compounds.
Pharmacognosy is the study of medicinal plants and natural products. The term was introduced in 1815 and comes from Greek roots meaning "drug" and "knowledge." It involves the study of plants as potential drug sources from pre-historic use through various civilizations like Chinese, Babylonian, Egyptian, Indian, and Greek. Modern pharmacognosy has broad applications in medicine, agriculture, cosmetics, and other industries and offers career opportunities in academia, private industry, and government.
Pharmacognosy is the study of drugs from natural sources such as plants, animals, and minerals. It developed from ancient civilizations using plant and animal parts for medicine. Through trial and error, early humans acquired knowledge about healing properties and passed this down generations. Modern pharmacognosy involves scientifically studying crude drugs, classifying them, and establishing standards for identification, quality, and purity in pharmacopoeias like the Indian Pharmacopoeia to ensure safety and efficacy of natural medicines.
Pharmacognosy is the study of medicines derived from natural sources. It deals with the physical, chemical, biochemical and biological properties of drugs from natural origins, as well as the search for new drugs. The history of pharmacognosy dates back to ancient civilizations in China, India, Egypt and Greece where plants were used medicinally before the beginning of the Christian era. Modern pharmacognosy developed between 1934-1960 due to events like the discovery of penicillin and isolation of compounds like reserpine. Today, pharmacognosy plays an important role in drug development through the isolation of active constituents, elucidation of their structures, and use of natural products as precursors for drug synthesis. Its future prospects
This document provides an introduction and overview of pharmacognosy. It defines pharmacognosy as the study of medicinal products from natural sources, including plants, animals, and minerals. The document then discusses the historical development of pharmacognosy from ancient civilizations like Babylon, Egypt, India, Greece, and China to modern developments. It also outlines the scope of pharmacognosy, including isolation of phytochemicals, structure-activity relationships, cultivation of medicinal plants, herbal formulations, and investigation of biosynthetic pathways. Finally, it briefly introduces some traditional medicine systems like Ayurveda, Unani, Siddha, and Homeopathy.
Introduction of Pharmacognosy, Scope and Traditional system of MedicineSHIVANEE VYAS
The term Pharmacognosy comes from two Greek words: “Pharmakon" meaning drug or medicine, and "gnosis" meaning knowledge or study. Pharmacognosy also defined as the systemic study of crude drugs obtained from natural origin like plants, animals, minerals, and microbes. Pharmacognosy defined as the branch of science which involves details study of drug obtained from natural origin including name, collection, cultivation, macroscopy, microscopy, physical property, chemical constituents, therapeutic action and uses.
https://youtu.be/gxOVfntCCB8
Pherecydes Pharma has launched the Phagoburn clinical trial, the first international clinical study to evaluate the effectiveness of phage therapy in treating serious bacterial infections in burn victims. The randomized, controlled trial will involve 220 patients across 11 hospitals in France, Switzerland, and Belgium. If shown to be safe and effective, phage therapy could provide an alternative or supplement to antibiotics for treating antibiotic-resistant infections.
Pharmacognosy deals with plants and animals that yield drug substances, their properties, methods of harvesting crude drugs, processing, storing, and extracting active constituents. It also involves the identification, cultivation, collection, drying, and other processing of crude drugs. Key factors that affect medicinal plants include environmental conditions, soil contents, growth regulators, and genetics. Proper identification of the biological and geographical source of crude drugs is important for ensuring the right material is obtained.
There are four main sources of drugs:
1) Natural sources including plants, animals, microorganisms, and minerals. Plants have historically been an important source and provide drugs like morphine, codeine, and digitalis.
2) Semi-synthetic drugs which are produced from natural compounds through chemical processing to make them less impure, like 6-aminopencillanic acid.
3) Synthetic drugs which are produced entirely in pharmaceutical laboratories and account for over 90% of drugs today. Examples include older drugs like chloroform as well as newer antipyretics, sulphonamides, and anti-anxiety drugs.
4) Recombinant DNA technology allows production of drugs like
Why Genetically Modified Maize Should Be BannedSeeds
The document summarizes concerns about the genetically modified maize 1507, which is tolerant to the herbicide glufosinate and produces an insecticide. It argues that the maize poses risks to the environment and biodiversity if cultivated commercially due to gaps in its risk assessment. Specifically, the effects of the maize's herbicide tolerance and impacts on non-target organisms like butterflies, bees and soil life have not been adequately studied. The European Food Safety Authority is criticized for not requiring further studies before approval and for proposing insufficient monitoring plans. Approval of the maize for cultivation is not recommended.
Pharmacognosy is "the study of the physical, chemical, biochemical and biological properties of drugs, drug substances or potential drugs or drug substances of natural origin as well as the search for new drugs from natural sources".
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
Herbal Ingredient in Food Suppliments By Anton.pptRehanAnis1
1. The document discusses establishing clear rules for evaluating the safety and efficacy of herbal ingredients in food supplements. It proposes a decision tree to differentiate products based on intended use and potential risks.
2. A procedure is outlined for evaluating safety based on the plant, extraction method, exposure, and available data. Dossiers would document quality control. Physiological effects are separated from pathological claims.
3. Indications considered physiological include heart health, capillary fragility, and minor issues. Therapeutic claims are proposed for vein issues, diarrhea, pain, and mild infections. Clear labelling is important to avoid misunderstanding about effectiveness.
This document discusses herbal cough remedies and regulation of herbal medicines. It provides epidemiological data showing widespread use of herbal medicines globally, with up to 80% of the population in Africa using traditional herbal medicine. Herbal medicines account for a significant portion of the pharmaceutical market. The document then reviews WHO guidelines for quality, safety and efficacy assessment of herbal medicines and compares regulation standards between countries like Germany, Egypt, and the United States. It also lists some common herbal cough remedies available in Egypt.
Regulatory requirements on herbal drugs understading the global perspectivessuserd3ff07
This document discusses regulatory requirements for herbal drugs from a global perspective. It outlines challenges countries face in regulating herbal medicines, including assessing safety and efficacy, quality control, and monitoring adverse effects. Regulations vary significantly between countries and regions. Europe implemented strict regulations after an herbal supplement mix-up caused kidney failure in thousands of women. The US regulates herbal supplements as dietary supplements rather than drugs. Other countries discussed include India, Malaysia, Singapore, China, the Philippines, Nigeria, Saudi Arabia, Australia, Canada, and Japan. The conclusion emphasizes the need for standardized, strengthened global regulation of herbal medicines given increased use and reports of adverse effects.
This document presents information on various herbal pharmacopoeias from around the world. It discusses the purpose of herbal pharmacopoeias to establish standards for herbal medicines. Key herbal pharmacopoeias discussed include the Ayurvedic Pharmacopoeia of India, European Herbal Pharmacopoeia, British Herbal Pharmacopoeia, United States Herbal Pharmacopoeia, Korean Herbal Pharmacopoeia, West African Herbal Pharmacopoeia, and Chinese Pharmacopoeia. The document concludes that modern herbal pharmacopoeias establish standards for quality and composition of herbal medicines to help ensure safe and effective use.
This document discusses pharmacovigilance as it relates to herbal medications. It defines pharmacovigilance and outlines its goals of improving patient safety, public health, and risk assessment of medicines. It then discusses specific challenges in monitoring the safety of herbal medicines, including quality control issues due to their complex chemical profiles. Several methods for herbal pharmacovigilance are described, including spontaneous adverse event reporting, prescription event monitoring, and reporting by herbal practitioners. Some herbs with known safety risks are highlighted as examples.
The use of herbal drugs for the prevention and treatment of various health ailments has been in practice from time immemorial. Generally it is believed that the risk associated with herbal drugs is very less, but reports on serious reactions are indicating to the need for development of effective marker systems for isolation and identification of the individual components.Standards for herbal drugs are being developed worldwide but as yet there is no common consensus as to how these should be adopted. Standardization, stability and quality control for herbal drugs are feasible, but difficult to accomplish. Further, the regulation of these drugs is not uniform across countries. There are variations in the methods used across medicine systems and countries in achieving stability and quality control. The present study attempts to identify the evolution of technical standards in manufacturing and the regulatory guideline development for commercialization of herbal drugs.
Keywords: survey was conducted to obtain primary data on challenges faced during production, commercialization, and marketing approval for traditional or herbal drugs in India and abroad. Responses were collected from companies by email, telephone, and in-person interviews and were analyzed to draw appropriate conclusions.The use of plants, parts of plants and isolated phytochemicals for the prevention and treatment of various health ailments has been in practice from time immemorial. It is estimated that about 25% of the drugs prescribed worldwide are derived from plants and 121 such active compounds are in use. Of the total 252 drugs in WHO's essential medicine list, 11% is exclusively of plant origin The use of plants, parts of plants and isolated phytochemicals for the prevention and treatment of various health ailments has been in practice from time immemorial. It is estimated that about 25% of the drugs prescribed worldwide are derived from plants and 121 such active compounds are in use. Of the total 252 drugs in WHO's essential medicine list, 11% is exclusively of plant origin .
This document provides a monograph for Bulbus Allii Cepae (onion bulb). It includes the following key information:
- The definition, synonyms, selected vernacular names, description, and plant material of interest for onion bulb.
- Guidance on the general appearance, identity, purity, chemical assays, and major chemical constituents for quality control purposes.
- Information on the dosage forms, medicinal uses supported by clinical data and traditional medicine, as well as the pharmacology, precautions, and posology for onion bulb.
Monographs Of Herbal Drugs and Comparative Study In Various Pharmacopoeias.VidyaNani
This document provides a comparison of herbal monographs from three pharmacopoeias: the Ayurvedic Pharmacopoeia of India (API), British Herbal Pharmacopoeia (BHP), and American Herbal Pharmacopoeia (AHP). It outlines the typical contents of monographs from each, such as definitions, descriptions, chemical assays, and qualitative standards. The API focuses on ayurvedic herbs, while the BHP and AHP include Western and traditional medicine herbs. The AHP contains the most therapeutic information, while the API and BHP emphasize identification and purity. Harmonizing formats across pharmacopoeias can help ensure the quality, safety and efficacy of herbal medicines.
The document discusses regulations for herbal drugs and quality standards. It outlines World Health Organization guidelines for authentication, contaminants testing, and other quality control of herbal drugs. It then describes regulations for herbal drugs in India, the United States, Australia, Canada, and the European Union. It also discusses Schedule T of the Indian Drugs and Cosmetics Act, which lays out good manufacturing practices, and potential interactions between herbal medicines and conventional drugs.
Following file comprises of information about interactions taking place between herbs-drug, herbs-herbs, it also highlights some of the cases of clinical laboratory test interactions taking place due to use of herbal medicines.
This document provides an introduction to the subject of pharmacognosy. It defines pharmacognosy as the study of crude drugs from plant, animal, and marine sources. The document outlines the history and development of pharmacognosy over time with contributions from scientists since ancient times. It describes the scope of pharmacognosy, including understanding drug actions, formulating products, isolating phytochemicals, and more. The types of crude drugs are categorized as organized (containing tissues) or unorganized. Sources of crude drugs are discussed, including various plant parts, animals, marine organisms, and tissue culture techniques.
The document discusses herbal medicines and natural products. It introduces pharmacognosy as the study of medicinal plants and natural products used as medicines. Herbal medicines contain complex mixtures of compounds derived from plants, while pure natural products contain single or a few active compounds. Quality control and production processes are important for both herbal medicines and pure natural products to ensure safety and efficacy. Regulations provide frameworks for traditionally used herbal medicines.
Herbal medications and Nutritional supplementsEneutron
Botanicals (Herbal Medications) & Nutritional Supplements discusses botanicals and dietary supplements. It provides an overview of their historical use and regulation in the US. Specifically, it discusses Echinacea and Garlic, covering their chemistry, pharmacologic effects, clinical trials, adverse effects, interactions and dosing. For Echinacea, it summarizes that while some trials found it reduced cold symptoms, recent ones using different species found no benefit. For both, it emphasizes the need for more research on safety and efficacy.
Ethnobotany and ethnopharmacology involve the scientific study of how different ethnic groups use plants for medicinal purposes. The document discusses the impact of ethnobotany on herbal drug evaluation and traditional medicine. It describes how ethnobotany helps identify new plant-based drugs and molecular models through processes like bioassay-guided purification and structure elucidation. Ethnopharmacology plays a key role in evaluating traditionally used herbal medicines and validating their therapeutic effects through controlled clinical studies.
This document provides an overview of herbal monographs and guidelines for herbal drugs. It discusses the purpose and importance of herbal monographs in authenticating herbal materials. It describes different types of monographs, including standards monographs, therapeutic monographs, and combined monographs. The document also compares the content and format of monographs from various pharmacopoeias and authoritative sources, such as the Indian Pharmacopoeia, United States Pharmacopoeia, Ayurvedic Pharmacopoeia of India, and World Health Organization.
This chapter discusses various methods for classifying crude drugs, including alphabetical, taxonomic, morphological, pharmacological, chemical, chemotaxonomic, and serotaxonomic classification. The alphabetical classification method arranges crude drugs in alphabetical order by their Latin, English, or local names and is the simplest approach. However, it does not consider the biological relationships between drugs. The taxonomic classification method classifies drugs according to their taxonomic ranks, from kingdom to species, providing information on their biological relationships but it can be complex. Other classification methods organize drugs based on their morphology, pharmacological effects, chemical constituents, or time of collection. Each method has its own strengths and weaknesses.
Bpharm 2 y_4s_405t_pharmacognosy & phytochemistry-iNop Pirom
Pharmacognosy is the study of crude drugs from plants, animals, and minerals. Most crude drugs used in medicine are obtained from plants and include parts like leaves, roots, bark, and seeds. Crude drugs may consist of entire plants or animals or their extracts. Organized drugs are direct plant parts containing cellular tissue, while unorganized drugs do not contain tissue and are prepared through processes like drying or extraction. Pharmacognosy studies these natural substances and their chemical constituents for medical uses as well as in cosmetics, textiles, and food industries. The field has broad applications in academia, private industry, and government agencies.
This document discusses the need for standardization of herbal medicines to ensure safety and quality. It notes that over 80% of people globally use herbal medicines, but a lack of quality control has led to issues like adulteration. The review aims to educate stakeholders on establishing parameters for collection, processing, production and quality assurance of herbal medicines. It discusses how standardization is important given the natural variability of herbal products and lack of regulation in many countries. Proper standardization would help develop consistent quality and identity of herbal medicines.
This presentation by Tim Capel, Director of the UK Information Commissioner’s Office Legal Service, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
The importance of sustainable and efficient computational practices in artificial intelligence (AI) and deep learning has become increasingly critical. This webinar focuses on the intersection of sustainability and AI, highlighting the significance of energy-efficient deep learning, innovative randomization techniques in neural networks, the potential of reservoir computing, and the cutting-edge realm of neuromorphic computing. This webinar aims to connect theoretical knowledge with practical applications and provide insights into how these innovative approaches can lead to more robust, efficient, and environmentally conscious AI systems.
Webinar Speaker: Prof. Claudio Gallicchio, Assistant Professor, University of Pisa
Claudio Gallicchio is an Assistant Professor at the Department of Computer Science of the University of Pisa, Italy. His research involves merging concepts from Deep Learning, Dynamical Systems, and Randomized Neural Systems, and he has co-authored over 100 scientific publications on the subject. He is the founder of the IEEE CIS Task Force on Reservoir Computing, and the co-founder and chair of the IEEE Task Force on Randomization-based Neural Networks and Learning Systems. He is an associate editor of IEEE Transactions on Neural Networks and Learning Systems (TNNLS).
1.) Introduction
Our Movement is not new; it is the same as it was for Freedom, Justice, and Equality since we were labeled as slaves. However, this movement at its core must entail economics.
2.) Historical Context
This is the same movement because none of the previous movements, such as boycotts, were ever completed. For some, maybe, but for the most part, it’s just a place to keep your stable until you’re ready to assimilate them into your system. The rest of the crabs are left in the world’s worst parts, begging for scraps.
3.) Economic Empowerment
Our Movement aims to show that it is indeed possible for the less fortunate to establish their economic system. Everyone else – Caucasian, Asian, Mexican, Israeli, Jews, etc. – has their systems, and they all set up and usurp money from the less fortunate. So, the less fortunate buy from every one of them, yet none of them buy from the less fortunate. Moreover, the less fortunate really don’t have anything to sell.
4.) Collaboration with Organizations
Our Movement will demonstrate how organizations such as the National Association for the Advancement of Colored People, National Urban League, Black Lives Matter, and others can assist in creating a much more indestructible Black Wall Street.
5.) Vision for the Future
Our Movement will not settle for less than those who came before us and stopped before the rights were equal. The economy, jobs, healthcare, education, housing, incarceration – everything is unfair, and what isn’t is rigged for the less fortunate to fail, as evidenced in society.
6.) Call to Action
Our movement has started and implemented everything needed for the advancement of the economic system. There are positions for only those who understand the importance of this movement, as failure to address it will continue the degradation of the people deemed less fortunate.
No, this isn’t Noah’s Ark, nor am I a Prophet. I’m just a man who wrote a couple of books, created a magnificent website: http://www.thearkproject.llc, and who truly hopes to try and initiate a truly sustainable economic system for deprived people. We may not all have the same beliefs, but if our methods are tried, tested, and proven, we can come together and help others. My website: http://www.thearkproject.llc is very informative and considerably controversial. Please check it out, and if you are afraid, leave immediately; it’s no place for cowards. The last Prophet said: “Whoever among you sees an evil action, then let him change it with his hand [by taking action]; if he cannot, then with his tongue [by speaking out]; and if he cannot, then, with his heart – and that is the weakest of faith.” [Sahih Muslim] If we all, or even some of us, did this, there would be significant change. We are able to witness it on small and grand scales, for example, from climate control to business partnerships. I encourage, invite, and challenge you all to support me by visiting my website.
This presentation by OECD, OECD Secretariat, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
11June 2024. An online pre-engagement session was organized on Tuesday June 11 to introduce the Science Policy Lab approach and the main components of the conceptual framework.
About 40 experts from around the globe gathered online for a pre-engagement session, paving the way for the first SASi-SPi Science Policy Lab event scheduled for June 18-19, 2024 in Malmö. The session presented the objectives for the upcoming Science Policy Lab (S-PoL), which featured a role-playing game designed to simulate stakeholder interactions and policy interventions for food systems transitions. Participants called for the sharing of meeting materials and continued collaboration, reflecting a strong commitment to advancing towards sustainable agrifood systems.
• For a full set of 530+ questions. Go to
https://skillcertpro.com/product/servicenow-cis-itsm-exam-questions/
• SkillCertPro offers detailed explanations to each question which helps to understand the concepts better.
• It is recommended to score above 85% in SkillCertPro exams before attempting a real exam.
• SkillCertPro updates exam questions every 2 weeks.
• You will get life time access and life time free updates
• SkillCertPro assures 100% pass guarantee in first attempt.
This presentation by Katharine Kemp, Associate Professor at the Faculty of Law & Justice at UNSW Sydney, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
This presentation by Professor Giuseppe Colangelo, Jean Monnet Professor of European Innovation Policy, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
The Intersection between Competition and Data Privacy – COLANGELO – June 2024...
Vittorio silano
1. CATEGORIZATION OF HERBAL PRODUCTS :
TRADITIONAL FOOD SUPPLEMENTS
AND TRADITIONAL MEDICINAL PRODUCTS
Vittorio Silano
II University of Rome and
CEF Panel, European Food Safety
Authority
3. THE START OF THE PROCESS
During the last 12 years, botanicals and botanical prepa-
rations in use since long time (so called «traditional») on
the European market have been categorized by sectoral
EU regulations into two main categories, i.e. products
intended to:
correct altered physiological processes in case of
diseases or preventing their occurence (traditional
herbal medicinal products- THMP);
help the human body in maintaining its homeostasis
contributing to physiological processes or reducing
risk factors for specific diseases (traditional plant
food supplements- TBFS).
Often, in both cases, the nature of the active compo-
nents relieving/preventing disease symptoms or
exerting homeostatic effects is unknown.
4. TRADITIONAL BOTANICAL FOOD
SUPPLEMENTS
For traditional food supplements, including the
botanical ones, the framework legislation (Directive
2002/46/ EC) was adopted in 2002 and that on
nutrition and health claims (efficacy) was adopted in
2006 (Reg. (EC) 1924).
According to Reg. (EC) 258/1997, if evidence is
available to the effect that the product has been
present in the Community market in significant
amounts before 15 May 1997 no authorization is
needed to market the product and only a pre-
marketing notification of the label may be imposed by
Member States. If this condition is not fulfilled, the
food supplement is considered «novel» and a case
by case authorization at a Communty level is required.
5. TRADITIONAL HERBAL MEDICINAL PRODUCTS
For traditional herbal medicinal products, the
Directive 2004/24/EC) states that evidence has to be
available to the effect that the medicinal product in
question (or a corresponding product) has been in
use throughout a period of at least 30 years including
at least 15 years within the Community. A simplified
“traditional-use» registration (authorization) by
Member States Competent Authorities, is needed for
marketing these products in the EU .
Specific tasks are attributed to EMA to produce
Community herbal monographs and specific lists of
herbal substances, preparations and combinations
thereof for use in traditional herbal medicinal products
to facilitate the registration by national competent
Authorities.
6. The strange situation determined in the European
market of botanical products by the above-mentioned
legislations
Traditional Botanical Traditional Botanical
Food Supplements Medicinal Products
____________________ ___________________
Safety Uncertainty on how it Supported by EMA
it is assessed by manu- Monographs or by
facturers and supervised ad hoc assessment
by Member States in dif- case by case.
ferent countries . Substan-
tial differences are evident.
Efficacy Based on claims substan- Based on indications whose
tiated by generally accep- plausibility depends mainly
ted scientific data ( these from traditional use data.
data are generally unavai-
lable as shown by EFSA ).
Efficacy with Unclear Impossible
no claims/
Indications.
7. The strange situation determined in the European
market of botanical products by the above-mentioned
legislations
Although in theory the EU regulations have
established THMPs and TPFSs as two distinct
categories at an European level, a number of
botanical species which are marketed as food
supplements in some MSs are also marketed
as traditional medicinal products in other MSs.
The nature of the commercial botanical pro-
ducts made available to consumers in different
EU member States as traditional medicinal pro-
ducts or food supplements, currently depends,
more than from the intrinsic properties of the
botanical products and their ingredients,
mainly on the country under consideration.
8. Overlaps between THMPs and TPFSs
This is due to the fact that highly
heterogeneous preparations obtained from many
different botanical species and parts have been
used for long time before the EU harmonization
attempt and continue to be used in the
European Member States (MSs), as THMP or
TBFS, mainly depending on: the ((i) prevalent
medical and nutritional practices; (ii) cultural,
technological and social factors;(iii) pre-existing
national regulations; and/or (iv) availability in
each country of specific botanicals.
This condition is persisting in spite of the
adoption of the above-mentioned EU regulations
9. Table 1. Examples of different national approaches
for the marketing of selected botanical product
in MSs of the EU
1.Alium sativum (AU, BE and IT -Permitted as food
supplement ; BL and CY-an authorization is needed for
each product; Czech Rep., DE and IR-Permitted with
specific prescriptions ; FR-Not permitted, but it could
authorized ; SP e SW- It is considered a medicinal
product).
2. Ginkgo biloba (IT,NL and PL- Permitted as food
supplement; DE,GR,IR, SL, SP and SW- Not permitted
as it is considered a medicinal product; BE, Czech
Rep. and HON- Permitted, but only within maximum
levels).
10. Uptake of the traditional use registration scheme and
implementation of the provisions of Directive 2004/24/EC
in EU member States- Status 31 December 2011
The 10 most registered plants (used in mono-compo-
nent products -246 over 375 registrations in 2011) are:
Hyperici herba;Pelargonii radix; Harpagophyti radix;
Valeriana radix; Crataegi flium cum flore; Echinaceae
purpureae radix; Hippocas-tanum semen; Passiflorae
herba, Salvia officinalis folium and Melissae folium.
It is very easy to verify that these botanical species
and parts find very large use also as food
supplements.
11. Further evidence of the overlapd
between THMPs and TPFSs
Additional evidences of the large overlap of
botanical species between THMPs and TPFSs
are provided by a study carried out on 171
botanical species in 2011.
This study shows that not a single botanical
species is marketed in the EU only as food
supplement or medicinal product.
12. Double traditional uses of individual botanical
species as food medicinal products and food
supplements
Plant(s) –mono No of products Known food supple-
registered ment use (AEGSP
inventory)
Pelargonium sidoides 21 in 5 countries
Echinacea purpurea 17 in 7 “ limit.
Harpagophytum procubens 12 in 7 “ limit.
Valeriana officinalis 11 in 8 “ limit
Hypericum perforatum 9 in 7 “ limit.
Passiflora incarnata 7 in 11 “ limit.
Arnica montana 5 in 3 “ limit.
Rhodiolae roseae 4 in 6 “ limit.
Salvia officinalis 3 in 8 “ limit.
Tanacetum parthenium 3 in 5 “ limit.
Aesculus hippocastanum 2 in 4 “ limit
13. Double traditional uses of individual botanical
species as food medicinal products and food
supplements
Botanical species Community List AESGP Food Supp.
of traditional use catalogue
medicinal products (No. of countries)
___________________ ________________ _____________
Calendula officinalis Yes 8
Echinacea purpurea Yes 7
Eleutherococcus senticosus Yes 5
Foeniculum vulgare var. dulce Yes 7
Foeniculum vulgare var. bitter Yes 7
Linum usitatissimum Yes 6
Pimpinella anisum L. Yes 8
Mentha piperita Yes 7
Valeriana officinalis Yes 2
14. Food supplement use in different countries of
traditional botanical species with an EMA
Monograph concerning medicinal use
Echinacea pallida (4); - Sambucus nigra (9);
Equisetum arvense (7); - Solidago spp (3);
Melilotus officinalis (4); - Betula spp (6)
Plantago ovata (7); - Centaure cyanus (7)
Primula spp (5); - Harpagophitum
procumbens (2);
Frangula purshiana (2); - Polypodium vulgare (3)
Salix alba (4); - Ruscus aculeatus (4);
Urtica spp (4); - Thymus spp (3);
Aloe vera (7); - Verbascum spp. (6)
Althea officinalis (6); - Melissa offcinalis (8)
Avena sativa (8); - Passiflora spp (3)
------------------------------
In parenthesis the number of countries in which the botanical
species is used as food supplements
15. Botanical species registered in selected countries
under Directive 2004/24/EC ( and relative indications)
that are also used as food supplements in other
European countries
AU: Passiflora incarnata-uneasiness, stress, sleeping disorders and
agitation (4); Pelargomium sidoides- cold (5); Arnica – muscles and
joints ; Capsicum- muscles and joints (3); Rhodiolae rosa-stress (4);
Harpagophytum procumbens- rheumatic pain (7).
FI: Gingo biloba- cold hands and feet due to mild bloodflow disruption
in periferal vessels (2).
DE: Melissa officinalis- nervousness, tension, anxiety and headaches
(8); Crataegus spp-circulatory functions; Levisticum officinale (8) plus
Centaurium erythraea (8) and Rosmarinus officinalis (8)- inflammatory
diseases of the lower urinary tract and decrease of kidney stones(8);
Graminis- ; Valeriana -stress and sleep(2).
GR: Harpagophytum procumbens-minor articular pain(7);
Eleutherococcus senticosus – asthenia due to fatigue and weakness
(5).
---------------
In parenthesis the number of countries in which the botanical species is
used as food supplements
16. Botanical species registered in selected countries
under Directive 2004/24/EC ( and relative indications)
that are also as food supplements in other European
countries
NL: Pelargonium sidoides- cold (5) ;
SR: Crataegus spp. (8) plus Melissa officinalis (8) and
Valeriana(2) - support of cardiovascular system under stress and
convalescence;
SL: Crataegus spp. (8)-support of cardiac and circulatory
functions; Crataegus spp. (8) plus Passiflora spp.(4)- support of
cardiac and circulatory functions and mild nervous heart
complaints; Primula spp (5) plus Thymus (3)-cold; Plantago spp
(6) plus Malva sylvestris (6)- cold; Valeriana (2) plus Melissa spp
(8), Mentha piperita (7) and Lupulus- mental stress and aid sleep;
----------------------------------
In parenthesis the number of countries in which the botanical
species is used as food supplemennts
17. Botanical species registered in selected countries
under Directive 2004/24/EC ( and relative indications) that
are also as food supplements in other EU countries
SW: Rhodiola rosea (3)- fatigue and sensation of
weakness; Pinus mugo(4) plus Citrus limon (5),
Illicium verum (6),Foeniculum vulgare (7); Eucalyptus
globulus (6), Mentha piperita (6), Thymus vulgaris (5),
Tilia cordata (5), Pimpinella anisum (8), Carum carvi
(8), Polygonum aviculare (4) – cold symtoms and
occasional cough.
---------------------------------
In parenthesis the number of countries in which the
botanical species is used as food supplements
18. Botanical species registered in selected countries under
Directive 2004/24/EC ( and relative indications) that are
also as food supplements in other European countries
UK: Arnica montana (1) ; Harpagophytum
procumbens-minor articular pain(7); Tanacetum
parthenium (5)- migraine headaches;Cimicifuga
racemosa (2)-symptoms of the menopause; Serenoa
repens (6)- benign prostatic hypertrophy;Vitex agnus
castus-sleep disturbances; Valeriana officinalis (2)-
sleep disturbances; Aesculus hippocastanum-low
mood and mild anxiety; Pelargonium sidoides (5)-
cold; Echinacea purpurea (7)-common cold and
influenza type infections; Rhodiolae rosa-stress (4);
Hypericum perforatum (2)-low mood and slight
anxiety.
----------------------------------------
In parenthesis the number of countries in which the
botanical species is used as food supplements
19. THE MARKET EVIDENCE: Annual sales of traditional
botanical products being marketed in selected
countries as food supplements and medicinal
products (Expert Estimates-Year 2011-2012)
Country Botanical Food Total (i.e. Botanical
Supplements Food Supplements
plus Botanical Medi-
cinal Products )
------------- -------------- -------------------------
Italy 1454 1500
Germany 841 2400
France 532 1500
____________________
(+)Millions of euros
20. Recommendations(1)
It woud be advisable that the European Commission
and Member States, with the collaboration of EFSA
and EMEA, undertake a new ad hoc collaborative
effort to improve and further harmonize the current
regulatory and scientific framework by developing:
- a practical approach to better identify/characterize
botanical species and preparations more suited for
use as food supplements or medicinal products;
- a harmonized approach to safety and efficacy asses-
sment of both typologies of products, preferably
based on traditional use, to be used throughout the
EU in a substantially coherent manner.
21. Recommendations (2)
1. Botanical food supplements are intended to
complement the normal diet, whereas medicinal
products should be mainly intended for treating or
preventing specific symptoms of disease;
2. Botanical food supplements could be for lifetime
exposure, whereas this is not generally the case for
medicinal products;
3. Even for products based on the same botanical
species and parts of the plant, dietetic long-term use
levels should likely to be lower that those applicable
to medicinal products;
4. Indications of use for food supplements and me-
dicinal products should be clearly different;
5. Timely ad hoc MS measures should be adopted to
facilitate reorganization and restructuring of relevant
commercial sectors where needed.